Approved

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

USFDA Approves Evofem Biosciences' Phexxi, the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

Duchesnay

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine

Lead Product(s): Ospemifene

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Plushcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 19, 2020

Details:

The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of their own home.

Ferring Pharmaceuticals Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births

Lead Product(s): Carbetocin

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

Carbetocin Ferring is the first medicine approved under the new Swissmedic and Marketing Authorisation for Global Health Products (MAGHP) procedure, which aims to build capacity and speed up access to essential medicines in low- and middle-income countries.

Mithra Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

Lead Product(s): Etonogestrel,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Gynial

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 05, 2020

Details:

Under the terms of this agreement, Gynial will distribute Myring™ in Switzerland, where the Swiss contraceptive rings market is worth EUR 8 million per year.

Afaxys Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

TherapeuticsMD and Afaxys Enter Into Agreement

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticsMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 13, 2020

Details:

The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely

Lead Product(s): Estradiol,Nomegestrol Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 22, 2020

Details:

Theramex currently markets Zoely® in eleven European countries, and this transaction will bring the total number of more than 50 on a global basis. MSD retains rights in the United States and Canada.

Mithra Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market

Lead Product(s): Etonogestrel,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Farmitalia

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 21, 2020

Details:

Under the terms of the agreement, Farmitalia will distribute Myring™ in Italy, which is the third largest worldwide vaginal contraceptive ring market in terms of sales value and volume, after the US & Germany.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Evofem Biosciences

USFDA Approves Evofem Biosciences' Phexxi, the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Duchesnay

Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine

Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births

Mithra Pharmaceuticals

Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring™ in Switzerland

Afaxys Pharma

TherapeuticsMD and Afaxys Enter Into Agreement

Merck & Co. Inc.

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely

Mithra Pharmaceuticals

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market